What now in HCV?
The euphoria-inducing near-100% cure rates seen with the new wave of hepatitis C therapies at the European Association for the Study of the Liver (EASL) International Liver Congress in London from 9-13 April have been a highlight of the year, and, some would say, the decade so far. But will the devil be in the detail, and how will the market play out when there are several companies all limbering up to launch highly effective treatments following Gilead Sciences' early lead with Sovaldi (sofosbuvir)?
Datamonitor Healthcare analysts Michael Haydock and Christina Vasiliou attended the conference and produced a white paper on the key findings, breaking down the various trial read-outs presented and also examining the patient access issues that are expected to result from the high prices of the new treatments.
Scrip collared Mr Haydock to pick his brains on the likely market dynamics.
Share This Article
